سعر نورموتنسيل 2مجم 7 اقراص 2022

Lacidipine 2 mg film-coated tablets, pack of 7 (Unipharma, Egypt); vascular-selective dihydropyridine calcium channel blocker for hypertension.

• Treatment of hypertension, alone or in combination with other antihypertensive agents (including beta-blockers, diuretics and ACE inhibitors).Population: Adultselectronic medicines compendium (eMC), MHRA-authorised SmPC

• Generally well tolerated; side effects are mainly related to peripheral vasodilation.International label, same formulation · electronic medicines compendium (eMC), MHRA-authorised SmPC

• Hypersensitivity to lacidipine or excipients; aortic stenosis; use during or within one month of myocardial infarction; discontinue in cardiogenic shock or unstable angina. Use with great care after allergy to another dihydropyridine.International label, same formulation · electronic medicines compendium (eMC), MHRA-authorised SmPC

• May cause dizziness; patients should not drive or operate machinery if affected.International label, same formulation · electronic medicines compendium (eMC), MHRA-authorised SmPC

• Grapefruit juiceShould not be taken with grapefruit juice (bioavailability may be altered).electronic medicines compendium (eMC), MHRA-authorised SmPC
• Strong CYP3A4 inhibitors and inducers (e.g. itraconazole, rifampicin)Metabolised by CYP3A4; significant inhibitors or inducers may alter its metabolism and elimination.electronic medicines compendium (eMC), MHRA-authorised SmPC
• Other antihypertensivesAdditive hypotensive effect with other agents that lower blood pressure.electronic medicines compendium (eMC), MHRA-authorised SmPC

• No data on safety in human pregnancy; use only when potential benefit outweighs risk to the fetus or neonate. Possible relaxation of uterine muscle at term.International label, same formulation · electronic medicines compendium (eMC), MHRA-authorised SmPC
• Animal data suggest excretion into milk; use during breastfeeding only if benefit outweighs risk.International label, same formulation · electronic medicines compendium (eMC), MHRA-authorised SmPC

• Lacidipine: Specific, potent calcium antagonist with predominant selectivity for calcium channels in vascular smooth muscle; dilates peripheral arterioles, reducing peripheral vascular resistance and blood pressure (UK SmPC 5.1). Metabolised by CYP3A4; terminal half-life 13-19 h; absolute bioavailability ~10%.